Xybion Medical Licenses Calvert Labs To Produce Pristima

Xybion Medical, the developer of Pristima, has reported that Calvert Labs has licensed, validated and placed Pristima into production.

Using Xybion’s Standard Validation Package to accelerate its implementation and validation of Pristima, Calvert was able to leverage its internal resources to execute the validation along with Xybion’s installation, training and configuration services.

The company said that after extensive research to improve its ability to bring near-real time data to to their customers, Calvert selected Xybion’s Pristima solution to manage its general toxicology data as well as licensing Xybion’s Standard Validation Package. Additionally, Calvert contracted Xybion to provide a full suite of professional services in order to achieve a tailored solution to match Calvert’s needs.

Pradip Banerjee, CEO of Xybion, said: We are proud to add Calvert Labs to the Xybion client community. Their strategy to take on a wider variety of studies, offer more flexibility in their study designs and to make study reports available to clients quickly, fits right in with Xybion’s strategy to provide the most comprehensive, flexible, and powerful system on the market. We are tremendously satisfied that Calvert has acknowledged Xybion as its ideal information systems partner and is integrating the Pristima preclinical solution into its full array of products and services.

Allan Reiss, CEO of Calvert Labs, said: Our business differentiator is to offer clients a customised, responsive and proven approach to preclinical services. Xybion’s Pristima solution fit right in with our strategy.